Axsome bounces back as FDA clears depression drug
pharmaphorum
AUGUST 21, 2022
There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective. Following after is AXS-12 (reboxetine) for narcolepsy, which could be filed in 2023.
98 
Let's personalize your content